Konstantinos Leventakos, MD, PhD Mayo Clinic

Novel Treatment Approaches for SCLC and Future Perspectives

August 14th 2023

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.

2L Dosing Considerations and Management Strategies for SCLC

August 7th 2023

Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.

LAGOON and IMFORTE Trials: Data Updates and Expert Insights

August 7th 2023

A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.

Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy

July 31st 2023

A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.

Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond

July 31st 2023

Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.

Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC

July 24th 2023

Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer.

Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%

July 24th 2023

Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.

ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC

July 17th 2023

Faculty discuss potential treatment approaches for limited stage small-cell lung cancer currently under investigation in the ADRIATIC and other ongoing trials.

Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC

July 17th 2023

Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.

CASPIAN: Long-Term Follow-up Data and Potential Predictors for Treatment Outcomes

July 10th 2023

Expert oncologists discuss long-term data updates from the CASPIAN trial and the associated implications on clinical practice.

Expert Insights on First-line Treatment Strategies in SCLC

July 10th 2023

An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection.

Patient Scenario 1: Newly Diagnosed ES-SCLC With Presence of Hepatic and Brain Metastases

July 3rd 2023

A panel of expert oncologists present the case of a 68-year-old man with newly diagnosed, extensive stage small-cell lung cancer and brain metastases, who is treated with carboplatin, etoposide, and durvalumab, and provide their initial impressions.

Evolving Role of Biomarkers in SCLC

July 3rd 2023

Faculty discuss the evolving role of molecular markers in small-cell lung cancer and the need for future research to identify improved biomarkers for targeted treatment options.

Impact of Disease Staging on Prognosis and Treatment in SCLC

June 26th 2023

Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.

Importance of Early Referral and Diagnosis in Small-Cell Lung Cancer

June 26th 2023

Expert oncologists provide an overview of the landscape surrounding small-cell lung cancer and highlight the importance of early referral and diagnosis for overall patient outcomes.

Ongoing Research in Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Treatment After Progression on Front-Line Therapy in Extensive-Stage Small Cell Lung Cancer

December 11th 2020

First-Line Approach for Treating Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Results from the CASPIAN Trial for Extensive-Stage Small Cell Lung Cancer

December 11th 2020

Results from the IMpower133 Trial for Extensive-Stage Small Cell Lung Cancer

December 11th 2020